Waldenström’s Macroglobulinemia
Gebonden Engels 2016 9783319225838Samenvatting
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.
Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.
Specificaties
Lezersrecensies
Inhoudsopgave
Part I: Tumor Cells and microenvironment
1. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
2. Waldenström’s Macroglobulinemia Immunophenotype
3. Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis
4. Cytogenetics in Waldenström Macroglobulinemia (WM)
5. Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia
6. Molecular Pathways in Growth and Survival: Epigenomics
7. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia
8. Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment
Part II: Epidemiology and Genetic Predisposition
9. Epidemiology of Waldenström Macroglobulinemia
10. Genetic Predisposition to Waldenström Macroglobulinemia
11. Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
Part III Clinical Features
12. Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia
13. Neuropathy in Waldenström’s Macroglobulinaemia14. IgM Amyloidosis
15. The Bing-Neel Syndrome
16. Unusual Manifestations of IgM Monoclonal Gammopathies
Part IV: Laboratory Investigations
17. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
Part V: Response
18. Response Assessment in Waldenström’s Macroglobulinaemia
Part VI: Prognostic Factors
19. Risk Stratification in Waldenström MacroglobulinemiaPart VII: Treatment Options and Recommendations
20. Indications for Treatment of Waldenström’s Macroglobulinemia
21. Immunotherapy in Waldenström’s Macroglobulinemia
22. Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia
23. Signal Inhibitors in Waldenström’s Macroglobulinemia
24. High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia25. Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
26. Treatment Recommendations in Waldenström Macroglobulinemia
Rubrieken
- advisering
- algemeen management
- coaching en trainen
- communicatie en media
- economie
- financieel management
- inkoop en logistiek
- internet en social media
- it-management / ict
- juridisch
- leiderschap
- marketing
- mens en maatschappij
- non-profit
- ondernemen
- organisatiekunde
- personal finance
- personeelsmanagement
- persoonlijke effectiviteit
- projectmanagement
- psychologie
- reclame en verkoop
- strategisch management
- verandermanagement
- werk en loopbaan